Study Group: Generic Pharmaceuticals Economic Experts (Germany)
Council Members in this Study Group: 48
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Survey or engage members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
John Ansell, MBADirector
John Ansell Consultancy
John Ansell, MBA, has been the Director of John Ansell Consultancy, a pharmaceutical consulting firm in Thame, United Kingdom, since November 1990. Mr. Ansell has advised some 120 pharma, biotech and companies providing pharmaceutical services. He focuses on international marketing and business development...
David SykesPrincipal
PRMA Consulting Ltd.
David Sykes is the founding Partner of PRMA Consulting, United Kingdom. He is an expert in pricing, reimbursement, and health outcomes within pharmaceutical and medical device sectors. Mr. Sykes has over 14 years of blue chip experience at J&J, Lilly, and Organon within global, European and UK roles....
Jan HackerManaging Partner
Oberender & PartnerJan Hacker is the Managing Partner and Co-founder of Oberender & Partner, a leading Healthcare Consulting Company in Germany. Mr. Hacker has expertise in strategic hospital management and the development of market entry strategies for foreign companies. He is also a member of the board of EconoMedic...
- Patrick Da-Cruz
Project Manager
Oberender & Partner
Patrick Da-Cruz is a Project Manager at Oberender and Partner, part of Economedic AG, Germany. Previously, Mr. Da-Cruz has worked in different positions at Ratiopharm including Corporate Development and Corporate Purchasing. He has worked for over four years as a Management Consultant specializingin...
Dilip ShahChief Executive Officer
Vision Consulting GroupDilip Shah is the Chief Executive Officer of Vision Consulting Group, a strategic planning firm in India. Mr. Shah has over 40 years of experience in the pharmaceutical industry. He serves as Chair of the Management Committee of the International Generic Pharmaceutical Alliance, Secretary-General of...
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Generics seek brands, Big pharma seek generics!
July 1, 2009
Lupin Expands Branded Play | www.sunherald.com
Generic companies have the creative R&D to develop value-added products and compete head-to-head with branded companies Branded companies see generics as an easy way to add products for their sales teams
-
This is partly or totally looked at a New Model for Healthcare in the US???
June 8, 2009
IBM Outlines New Model for Healthcare | www-03.ibm.com
Basically it becomes clear that IBM pledges for need to build out the IT infrastructure. The described Medical Home Care is only "one minor new brick" - (not enough practically investigated or tested). The US health care system is the most expensive in the world - one way or the other!! One "brick"...
-
Nycomed’s Daxas takes an important step forward
May 12, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Nycomed files European marketing authorisation application for Daxas® in COPD | www.pipelinereview.com
With the recent setbacks to Almirall’s clidinium bromide – it is not now scheduled to re-enter the regulatory fray until late 2011/early 2012 - the way has opened up for the PDE4 inhibitor Daxas (roflumilast) to be the next big thing in COPD. If it can only overcome the final, regulatory hurdles,...
-
Solvay Strategy - the company appends a note
April 27, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Sanofi moves on Solvay's pharma division | www.ft.com
On April 22nd Solvay appended a note to its initial April 1st press release which we commented upon at the time (Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities) on its web site: http://www.solvay.com/services/newsfrompo/0,,73459-2-0,00.htm This...
-
Glaxo Stiefel deals with the dermatology question
April 21, 2009
John Ansell, MBA, Director, John Ansell Consultancy
Glaxo agrees $3.6bn Stiefel deal | www.ft.com
Dermatology, formerly a heritage area for GSK, currently accounts for less than 3% of the company's total pharmaceutical turnover. Incorporation of Stiefel's business will only bring this up to around 6%. Neither company has succeeded since the 1980s in developing genuinely novel dermatologicals...
Members in this Study Group include these company types:
- Consultancy, Pharma-Focused
- Consultancy, Healthcare-Focused
- Pharmaceuticals Manufacturer
- Pharmacy or Drug Store, Independent/Local
- Academic Institution*
- Academic Medical Center/Hospital or Clinic
- Individual/Small Consultancy
- Strategic Management
- Contract Research Organization, Independent/Small
- Drug Distributor, General or Full-Spectrum
- Law Firm (general practice/large)
- Office Based Private Practice or Clinic
- Professional or Industry Association*
Members in this Study Group often have these job titles:
- Director
- Owner
- Chief Executive Officer
- Consultant
- President
- Principal
- Partner
- Project Manager
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 740 |
| Biopharmaceutical Reimbursement Experts (EU) | 18 |
| Pharmacists in Germany | 15 |
| Pharmacists (EU) | 181 |
| Physicians (Germany) | 1174 |
| Medical Tourism Experts | 359 |
| Generic Pharmaceuticals Regulation Experts: Healthcare Consultants | 44 |